Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
暂无分享,去创建一个
Wafik S El-Deiry | W. El-Deiry | Zhaohai Yang | M. Y. Al-Marrawi | B. Saroya | M. Brennan | T. Dykes | Zhaohai Yang | Mhd Yaser Al-Marrawi | Bikramajit Singh Saroya | Matthew C Brennan | Thomas M Dykes
[1] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.
[4] M. Piccart,et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours , 2005, British Journal of Cancer.
[5] D. Strumberg,et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. , 2005, Clinical colorectal cancer.
[6] L. Lang. FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.
[7] Jeffrey W. Clark,et al. Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.
[8] K. Galal,et al. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. , 2011, Indian journal of cancer.
[9] G. Schwartz,et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Dirk Strumberg,et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines , 2005, Anti-cancer drugs.
[11] J. Barrett,et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Oza,et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[14] K. Flaherty,et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. , 2007, Cancer cell.
[15] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Shirasawa,et al. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. , 2012, Carcinogenesis.
[17] A. Adjei,et al. Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.
[18] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[19] M. Ratain,et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[20] W. El-Deiry,et al. Novel antineoplastics targeting genetic changes in colorectal cancer. , 2013, Advances in experimental medicine and biology.
[21] C. Willett,et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[23] D. Amadori,et al. 42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) , 2004 .
[24] R. Goldberg,et al. Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer. , 2004, Clinical colorectal cancer.
[25] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[26] D. Strumberg,et al. The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer , 2002, Oncology Research and Treatment.
[27] K. Flaherty,et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. , 2007, Cancer research.
[28] Hieu T. Do,et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.
[29] R. Pazdur,et al. Sorafenib for the Treatment of Advanced Renal Cell Carcinoma , 2006, Clinical Cancer Research.